Menagerie: A text-mining tool to support animal-human translation in neurodegeneration research
暂无分享,去创建一个
Halil Kilicoglu | Amanda P Beck | Charles A Sneiderman | Dongwook Shin | Caroline J Zeiss | Brent Vander Wyk | Natalie Zatz | C. Zeiss | C. Sneiderman | H. Kilicoglu | Dongwook Shin | A. Beck | B. Vander Wyk | Natalie Zatz | Brent Vander Wyk
[1] J. V. Van Raamsdonk,et al. Modeling Parkinson’s Disease in C. elegans , 2018, Journal of Parkinson's disease.
[2] A. Pisani,et al. Promising rodent models in Parkinson's disease. , 2018, Parkinsonism & related disorders.
[3] K. Mullane,et al. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity , 2019, Current protocols in pharmacology.
[4] A. Lang,et al. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era , 2016, Trends in Neurosciences.
[5] Michael B Bracken,et al. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? , 2014, BMJ : British Medical Journal.
[6] Isabelle Boutron,et al. Misrepresentation and distortion of research in biomedical literature , 2018, Proceedings of the National Academy of Sciences.
[7] V. Francardo,et al. Animal models of l-DOPA–induced dyskinesia: an update on the current options , 2012, Neuroscience.
[8] S. Lazic,et al. A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.
[9] L. Breger,et al. Genetically engineered animal models of Parkinson's disease: From worm to rodent , 2019, The European journal of neuroscience.
[10] Zhiyong Lu,et al. PubTator: a web-based text mining tool for assisting biocuration , 2013, Nucleic Acids Res..
[11] Marcus R Munafò,et al. Significance chasing in research practice: causes, consequences and possible solutions. , 2014, Addiction.
[12] Martin F. Porter,et al. An algorithm for suffix stripping , 1997, Program.
[13] Laurie M. Ryan,et al. NIA Commentary: Translational Issues in Alzheimer’s Disease Drug Development , 2012, Neuropsychopharmacology.
[14] F. Scheperjans. Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle. , 2016, Current opinion in neurology.
[15] G. Novack. Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy? , 2013, Translational vision science & technology.
[16] R. Harrison,et al. Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.
[17] Zhiyong Lu,et al. tmBioC: improving interoperability of text-mining tools with BioC , 2014, Database J. Biol. Databases Curation.
[18] R. Porter,et al. Failure to publish negative results: A systematic bias in psychiatric literature , 2017, The Australian and New Zealand journal of psychiatry.
[19] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[20] D. Howells,et al. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.
[21] R. Takahashi,et al. Parkinson’s disease pathogenesis from the viewpoint of small fish models , 2017, Journal of Neural Transmission.
[22] Allan R. Jones,et al. Conserved cell types with divergent features in human versus mouse cortex , 2019, Nature.
[23] Jianhua Li,et al. Analysis of Polarity Information in Medical Text , 2005, AMIA.
[24] C. Zeiss. Improving the predictive value of interventional animal models data. , 2015, Drug discovery today.
[25] I. Cuthill,et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.
[26] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[27] T. Südhof,et al. Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.
[28] J. Ioannidis. Extrapolating from Animals to Humans , 2012, Science Translational Medicine.
[29] J. Ioannidis. Acknowledging and Overcoming Nonreproducibility in Basic and Preclinical Research. , 2017, JAMA.
[30] J. Bolker,et al. Model organisms: There's more to life than rats and flies , 2012, Nature.
[31] P. Snoy. Establishing Efficacy of Human Products Using Animals , 2010, Veterinary pathology.
[32] Sophia Ananiadou,et al. Thalia: semantic search engine for biomedical abstracts , 2018, Bioinform..
[33] H. Allore,et al. Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease , 2017, PloS one.
[34] B. Brembs. Prestigious Science Journals Struggle to Reach Even Average Reliability , 2018, Front. Hum. Neurosci..
[35] B. Liu,et al. The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery , 2008, Fundamental & clinical pharmacology.
[36] M. Delong,et al. Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.
[37] A. Crossman,et al. Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[38] Ana Mlinarić,et al. Dealing with the positive publication bias: Why you should really publish your negative results , 2017, Biochemia medica.
[39] Chih-Jen Lin,et al. LIBLINEAR: A Library for Large Linear Classification , 2008, J. Mach. Learn. Res..
[40] Henning Hermjakob,et al. The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..
[41] G. Perry,et al. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities , 2016, Oncotarget.
[42] R. Nussbaum. The Identification of Alpha-Synuclein as the First Parkinson Disease Gene , 2017, Journal of Parkinson's disease.
[43] Laura Avanzino,et al. Rehabilitation for Parkinson's disease: Current outlook and future challenges. , 2016, Parkinsonism & related disorders.
[44] S. Fox,et al. Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. , 2015, Current topics in behavioral neurosciences.
[45] R. Ransohoff. All (animal) models (of neurodegeneration) are wrong. Are they also useful? , 2018, The Journal of experimental medicine.
[46] J. Jankovic,et al. Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics , 2019, Drugs.
[47] S. Lewis,et al. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia , 2016, Current neuropharmacology.
[48] C. Zeiss. From Reproducibility to Translation in Neurodegenerative Disease. , 2017, ILAR journal.
[49] Sampo Pyysalo,et al. brat: a Web-based Tool for NLP-Assisted Text Annotation , 2012, EACL.
[50] J. E. Kranz,et al. Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[51] J. Ioannidis,et al. P values in display items are ubiquitous and almost invariably significant: A survey of top science journals , 2018, PloS one.
[52] F. Collins,et al. Policy: NIH plans to enhance reproducibility , 2014, Nature.
[53] A. Lang,et al. Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.
[54] C. Elliott,et al. Neurophysiology of Drosophila Models of Parkinson's Disease , 2015, Parkinson's disease.
[55] Guy Beauchamp,et al. ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia , 2018, PloS one.
[56] John P. Overington,et al. Classification and analysis of a large collection of in vivo bioassay descriptions , 2017, PLoS Comput. Biol..
[57] Pierre Tufféry,et al. Accessing external innovation in drug discovery and development , 2015, Expert opinion on drug discovery.
[58] O. Rascol,et al. New treatments for levodopa‐induced motor complications , 2015, Movement disorders : official journal of the Movement Disorder Society.
[59] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[60] J. Volkmann. DEEP BRAIN STIMULATION II Deep Brain Stimulation for the Treatment of Parkinson’s Disease , 2004 .
[61] J. Lafuente,et al. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease. , 2017, International review of neurobiology.
[62] Marlies Leenaars,et al. Publication Bias in Laboratory Animal Research: A Survey on Magnitude, Drivers, Consequences and Potential Solutions , 2012, PloS one.
[63] P. Gubellini,et al. Animal models of Parkinson's disease: An updated overview. , 2015, Revue neurologique.
[64] S. Perrin. Preclinical research: Make mouse studies work , 2014, Nature.
[65] Zhiyong Lu,et al. GNormPlus: An Integrative Approach for Tagging Genes, Gene Families, and Protein Domains , 2015, BioMed research international.
[66] J. Ioannidis,et al. Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases , 2013, PLoS biology.
[67] Giuseppe Di Giovanni,et al. Animal models of early-stage Parkinson’s disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms , 2018, Journal of Neuroscience Methods.
[68] David S. Park,et al. Animal Models of Parkinson's Disease , 2011, Parkinson's disease.
[69] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[70] C. Perier,et al. Neurotoxin-based models of Parkinson's disease , 2012, Neuroscience.
[71] A. Schapira,et al. Why have we failed to achieve neuroprotection in Parkinson's disease? , 2008, Annals of neurology.
[72] J. Ioannidis,et al. Reproducibility in Science: Improving the Standard for Basic and Preclinical Research , 2015, Circulation research.
[73] Olivier Bodenreider,et al. Aggregating UMLS Semantic Types for Reducing Conceptual Complexity , 2001, MedInfo.
[74] H. Heng,et al. Heng Reductionism The Conflict Between Complex Systems and Correction , 2008 .
[75] E. Bézard,et al. Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies , 2013, Movement disorders : official journal of the Movement Disorder Society.
[76] P. Calabresi,et al. Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias , 2018, Movement disorders : official journal of the Movement Disorder Society.
[77] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[78] T. Curran. Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer , 2018, Open Biology.
[79] I. Cuthill,et al. Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.
[80] P. Pound,et al. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail , 2018, Journal of Translational Medicine.
[81] David B. Fogel,et al. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review , 2018, Contemporary clinical trials communications.
[82] Aidong Zhang,et al. A survey on literature based discovery approaches in biomedical domain , 2019, J. Biomed. Informatics.
[83] J. Winderickx,et al. Yeast models of Parkinson's disease-associated molecular pathologies. , 2017, Current opinion in genetics & development.
[84] M. Morissette,et al. Non-human primate models of PD to test novel therapies , 2018, Journal of Neural Transmission.
[85] Marcelo Fiszman,et al. The interaction of domain knowledge and linguistic structure in natural language processing: interpreting hypernymic propositions in biomedical text , 2003, J. Biomed. Informatics.